Healthcare · Drug Manufacturers - Specialty & Generic
Price
$3.80
Market Cap
$17.1M
Employees
17
Beta
0.40
Avg Volume
434,127
CEO
Zeeshan Saeed
Business Description
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.47
Stock Price: $3.80
EPS (Diluted): -8.11
EPS (Diluted): -8.11
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.47
Stock Price: $3.80
Total Equity: $6.91M
Shares: 3,285,876
Total Equity: $6.91M
Shares: 3,285,876
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.44
Market Cap: $17.06M
Total Debt: $1.87M
Cash: $1.90M
EBITDA: -$25.79M
Total Debt: $1.87M
Cash: $1.90M
EBITDA: -$25.79M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$24.0M
Market Cap: $17.06M
Total Debt: $1.87M
Cash: $1.90M
Total Debt: $1.87M
Cash: $1.90M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $3.80
Revenue: $0.00
Shares: 3,285,876
Revenue: $0.00
Shares: 3,285,876
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$15.30M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$26.18M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-621.8%
Net Income: -$26.18M
Total Equity: $6.91M
Total Equity: $6.91M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
819.1%
Operating Income: -$15.30M
Tax Rate: 0.0%
Equity: $6.91M
Total Debt: $1.87M
Cash: $1.90M
Tax Rate: 0.0%
Equity: $6.91M
Total Debt: $1.87M
Cash: $1.90M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.07
Current Assets: $6.47M
Current Liabilities: $6.05M
Current Liabilities: $6.05M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.27
Short-Term Debt: $1.87M
Long-Term Debt: $0.00
Total Debt: $1.87M
Total Equity: $6.91M
Long-Term Debt: $0.00
Total Debt: $1.87M
Total Equity: $6.91M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 3,285,876
Shares: 3,285,876
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$2.10
Total Equity: $6.91M
Shares: 3,285,876
Shares: 3,285,876
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-2.55
Operating CF: -$8.38M
CapEx: $0.00
Shares: 3,285,876
CapEx: $0.00
Shares: 3,285,876
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $3.80
Stock Price: $3.80
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$26.18M
Net Income: -$26.18M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares QNTM against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 9:26pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Expenses | $33.7M | $27.4M | $23.8M | $16.1M | $15.3M |
| Operating Income | -$33.7M | -$27.4M | -$23.8M | -$16.1M | -$15.3M |
| Net Income | -$35.3M | -$23.6M | -$17.9M | -$14.2M | -$26.2M |
| EBITDA | -$29.8M | -$22.1M | -$15.7M | -$14.4M | -$25.8M |
| EPS | $-65.63 | $-39.62 | $-29.39 | $-12.49 | $-8.11 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 9:26pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $35.3M | $17.0M | $2.8M | $6.0M | $1.9M |
| Total Current Assets | $45.9M | $17.9M | $11.1M | $12.1M | $6.5M |
| Total Assets | $63.0M | $38.4M | $17.5M | $17.1M | $11.1M |
| Current Liabilities | $8.7M | $7.8M | $4.6M | $6.7M | $6.0M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $8.8M | $7.9M | $4.6M | $6.7M | $6.0M |
| Total Equity | $54.1M | $30.5M | $13.2M | $11.5M | $6.9M |
| Retained Earnings | -$126.2M | -$144.2M | -$157.9M | -$172.1M | -$197.9M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 9:26pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$20.7M | -$28.3M | -$10.8M | -$6.9M | -$8.4M |
| Capital Expenditure | $-500,000 | $-363,958 | $0 | $0 | $0 |
| Free Cash Flow | -$21.2M | -$28.7M | -$10.8M | -$6.9M | -$8.4M |
| Acquisitions (net) | $768,964 | $0 | $31,783 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | -$1.9M | -$3.0M | $0 | $0 |
| Net Change in Cash | $17.7M | -$18.3M | -$14.2M | $3.2M | -$4.1M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 7:58am (1h ago)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$15.0M $15.0M – $15.0M
|
$25.6M $25.6M – $25.6M
|
$47.2M $47.2M – $47.2M
|
$258.0M $258.0M – $258.0M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$6.0M -$6.0M – -$6.0M
|
$0 | $0 | $0 |
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 9:26pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | +18.7% | +13.3% | +32.2% | +5.2% |
| Net Income Growth | +33.1% | +24.2% | +20.7% | -84.3% |
| EBITDA Growth | +25.8% | +28.9% | +8.6% | -79.4% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for QNTM — it's generated by the pipeline (
market-narrative step).
No community reviews yet for QNTM.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30